|1.||Thompson, Ian M: 52 articles (10/2015 - 12/2002)|
|2.||Goodman, Phyllis J: 28 articles (03/2015 - 12/2002)|
|3.||Tangen, Catherine M: 25 articles (03/2015 - 07/2003)|
|4.||Lippman, Scott M: 22 articles (10/2015 - 07/2003)|
|5.||Roehrborn, Claus G: 21 articles (06/2015 - 06/2002)|
|6.||Parnes, Howard L: 19 articles (10/2015 - 01/2005)|
|7.||Lucia, M Scott: 16 articles (10/2015 - 07/2003)|
|8.||Kaplan, Steven A: 15 articles (02/2015 - 10/2002)|
|9.||Coltman, Charles A: 15 articles (08/2008 - 07/2003)|
|10.||Till, Cathee: 14 articles (10/2015 - 03/2010)|
|1.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
11/01/2007 - "One hundred twenty patients with a clinical diagnosis of benign prostatic hyperplasia (BPH), sexually active and with an International Index of Erectile Function-erectile function (IIEF-EF) domain >/=25 were randomized to receive finasteride 5 mg concealed as an "X compound of proven efficacy for the treatment of BPH" for 1 year with (group 2) or without (group 1) counseling on the drug sexual side effect. "
05/01/2009 - "A significantly greater proportion of patients using multiple medications and finasteride were adherent with any benign prostatic hyperplasia medication (62% and 55%, respectively, p <0.0001). "
01/01/1995 - "The total, obstructive and non-obstructive symptom scores decreased (improved) for patients on 1 and 5 mg finasteride, with the total score reducing by 33% from baseline at year 3. The results demonstrate that finasteride causes a modest but significant clinical improvement in men with urinary outflow obstruction secondary to benign prostatic hyperplasia."
04/01/2008 - "Two landmark multi-centre trials, MTOPS and PCPT, have shown that finasteride is an effective treatment of micturitional disorders due to benign prostatic hyperplasia, reducing the clinical progression of BPH. "
07/24/2009 - "Finasteride is a mechanism-based inactivator of 5alpha-reductase type 2 with subnanomolar affinity and is widely used as a therapeutic for the treatment of benign prostatic hyperplasia. "
11/01/2014 - "Finasteride at a dose of 1 mg/d has been reported to show no significant improvement in 30-50% of patients with androgenetic alopecia (AGA). "
07/01/2015 - "In conclusion, continuous finasteride treatment for 5 years improved androgenetic alopecia with sustained effect among Japanese. "
01/01/2008 - "No study has shown that 1 mg of finasteride effectively treats female androgenetic alopecia but doses of 2.5 and 5 mg finasteride have helped some women in a few open studies. "
05/01/2008 - "Finasteride is a 5alpha-reductase inhibitor that has proved to be an effective treatment for men with androgenetic alopecia. "
08/01/2002 - "Finasteride 1 mg/day is effective in the treatment of androgenetic alopecia (AGA). "
|3.||Prostatic Neoplasms (Prostate Cancer)
06/01/2009 - "Several studies indicate that treatment with a 5ARI improves the performance of PSA testing for identifying men with prostate cancer, while the PCPT showed a significant reduction in the risk of developing prostate cancer with finasteride. "
08/01/1998 - "This study, using a novel model for evaluating short-term efficacy of chemopreventive or therapeutic agents in men at high risk of prostate cancer, provides little evidence that finasteride is an effective chemopreventive agent for prostate cancer in men with elevated PSA."
01/01/2009 - "Finasteride is found to be effective in significantly reducing the incidence of low-grade prostate cancer. "
11/01/2013 - "Studies show that treatment of men with 5α-reductase inhibitors such as finasteride is effective for the primary prevention of prostate cancer. "
09/01/2010 - "The Prostate Cancer Prevention Trial (PCPT) showed that finasteride was effective in reducing the incidence of prostate cancer. "
10/01/2002 - "In this study, hirsutism scores decreased significantly at 6 and 12 months in both groups I and II. Low-dose (2.5 mg/day) finasteride is safe and cost effective in the treatment of hirsutism and may be used instead of high-dose finasteride (5 mg/day) therapy."
11/01/1998 - "A significant improvement of hirsutism was obtained by finasteride; clinical score observed at the 6th month of therapy was reduced from 11.71 +/- 2.23 to 7.92 +/- 1.81 (p < 0.05) and from 14.92 +/- 6.13 to 9.3 +/- 2.75 (p < 0.05) in group A and B, respectively. "
08/01/1995 - "After 6 and 9 months of treatment, the hirsutism score improved significantly in the patients receiving finasteride, whereas no significant modifications were observed in patients treated with placebo. "
06/01/2014 - "Intermittent low-dose finasteride administration is effective for treatment of hirsutism in adolescent girls: a pilot study."
03/01/2001 - "We believe that Diane 35 plus finasteride is an effective and safe combination for the treatment of hirsutism."
01/01/2001 - "Finasteride has proved to be a safe, well tolerable and effective medication in reducing or preventing recurrent hematuria related to BPH."
11/01/1995 - "Finasteride is effective in treating hematuria associated with BPH. "
06/01/2002 - "Hematuria grade improved after finasteride in 50 (94%) patients. "
02/01/1998 - "Long-term follow-up has confirmed the efficacy of finasteride in treating gross hematuria associated with BPH and we now recommend finasteride as first line therapy in the treatment of BPH-associated gross hematuria. "
11/01/1995 - "Of the 12 patients with longer than 3 months of followup (mean 14) 11 improved according to the grade of hematuria after finasteride therapy. "
|3.||Cholestenone 5 alpha-Reductase (5 alpha-Reductase)
|2.||Drug Therapy (Chemotherapy)
|3.||Transplantation (Transplant Recipients)
|5.||Transurethral Resection of Prostate (TURP)